Methicillin Resistant Staphylococcus aureus (MRSA) causing
surgical site infections is one of the most common nosocomial infections
affecting post-surgery patients. Vancomycin is the recommended treatment
with MRSA-resistance breakpoint for minimum inhibition concentration (MIC)
of 2 ug/mL where the pathogen can be considered as susceptible. Here, we
describe the MIC of vancomycin against our MRSA isolates. Retrospective
data of MRSA positive cultures from post-surgical patients who were admitted
to the Clinical Training Centre Sungai Buloh public section from 2016-2017
with documented MIC to vancomycin were analyzed. The specimens consist
of pus swabs, mediastinal fluid, sternal bone, and tissue. A total of 29 MRSA
were isolated from 11 patients. There were 19, 3, 3 and 4 MRSA with
vancomycin’s MIC (ug/mL) of 0.5, 1, 1.5 and 2 respectively. The MRSA with
MIC of 2 ug/mL were observed from two different patients with one of them
showing MIC of 0.5 ug/mL which grew from wound swabs to 2.0 ug/mL which
grew from sternal bone and mediastinal fluid isolates. Vancomycin reduced
susceptibility MRSA has been observed in our clinical training centre with a
1.1% incidence. Identification of possible risk factors and follow up of
outcomes is required to fully elucidate the importance of this occurrence.